Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Vibeke Kruse

28 Results

2022

Biomarkers in immuno-oncology : from melanoma to other cancer types, from tissue to liquid biopsy, from late stage to early stage disease

Annabel MeiresonLieve BrochezLiesbeth FerdinandeVibeke Kruse

Mental health and quality of life among patients with cancer during the SARS-CoV-2 pandemic : results from the longitudinal ONCOVID survey study

Emiel De JaeghereHeini KanervoRoos ColmanWim SchrauwenPaulien WestNele VandemaeleAglaja De PauwCeline JacobsIngeborg HildersonMicky Saerens et al.

A1 Journal Article in CANCERS

Towards the discovery of prognostic and predictive biomarkers in CHEERS, a radioimmunotherapy phase II trial

Jan VanwelkenhuyzenMathieu SpaasKim Van der EeckenVibeke KruseSylvie RotteyLieve BrochezJohan LindbergKatleen De PreterBram De LaerePiet Ost

2021

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial

Mathieu SpaasNora SundahlEva HulstaertVibeke KruseSylvie RotteyDaan De MaeseneerVeerle SurmontAnnabel MeiresonLieve BrochezDries Reynders et al.

A1 Journal Article in BMC CANCER

Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures

Annabel MeiresonSimon TavernierSofie Van GassenNora SundahlAnnelies DemeyerMathieu SpaasVibeke KruseLiesbeth FerdinandeJo Van DorpeBenjamin Hennart et al.

A1 Journal Article in CANCERS

Managing viral hepatitis in cancer patients under immune checkpoint inhibitors : should we take the risk?

Stijn De KeukeleireTijl VermassenZahra Mosala NezhadTessa KerreVibeke KruseHans Van VlierbergheKarim VermaelenSylvie Rottey

A1 Journal Article in IMMUNOTHERAPY

Selective oral MEK1/2 inhibitor pimasertib : a phase I trial in patients with advanced solid tumors

Jean-Pierre DelordAntoine ItalianoAhmad AwadaPhilippe AftimosNadine HouédéCéleste LebbéCeline PagesThierry LesimpleMonica DinulescuJan H. M. Schellens et al.

A1 Journal Article in TARGETED ONCOLOGY

Selective oral MEK1/2 inhibitor pimasertib in metastatic melanoma : antitumor activity in a phase I, dose-escalation trial

Céleste LebbéAntoine ItalianoNadine HouédéAhmad AwadaPhilippe AftimosThierry LesimpleMonica DinulescuJan H. M. SchellensSuzanne LeijenSylvie Rottey et al.

A1 Journal Article in TARGETED ONCOLOGY

Spatiotemporal evolution of radiation myositis on 18F-FDG PET/CT following hypofractionated radiotherapy of intramuscular melanoma metastases

Mathieu SpaasBliede Van den BroeckDavid CreytensVibeke KrusePiet Ost

Editorial material

2020

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Yanina JansenVibeke KruseJurgen CorthalsKelly SchatsPieter-Jan van DamTeofila SeremetCarlo HeirmanLieve BrochezMark KockxKris Thielemans et al.

A1 Journal Article in CANCER IMMUNOLOGY IMMUNOTHERAPY

Recommendations for skin cancer consultation and surgery during COVID‐19 pandemic

Lieve BrochezJ.F. BaurainV. Del MarmolA. NikkelsVibeke KruseF. SalesM. StasA. Van LaethemM. Garmyn

Editorial material

2019

Boosting anticancer immunity with radiotherapy

Nora SundahlPiet OstVibeke KruseKarel Decaestecker

Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma

Nora SundahlTeofila SeremetJo Van DorpeBart NeynsLiesbeth FerdinandeAnnabel MeiresonLieve BrochezVibeke KrusePiet Ost

A1 Journal Article in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Throughput efficiency and service quality after process redesign at a cancer day care unit: Two sides of the coin?

Kaat De PourcqPaul GemmelJeroen TrybouVibeke Kruse

A1 Journal Article in EUROPEAN JOURNAL OF CANCER CARE

To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition

Stijn De KeukeleireTijl VermassenGert De SchoenmakereVibeke KruseKarim VermaelenSylvie Rottey

A1 Journal Article in ACTA CLINICA BELGICA

2018

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

Lieve BrochezAnnabel MeiresonInes ChevoletNora SundahlPiet OstVibeke Kruse

A1 Journal Article in NATURE COMMUNICATIONS

Endothelial indoleamine 2,3-dioxygenase is correlated with microsatellite status in colorectal carcinoma and predicts worse prognosis

Annabel MeiresonInes ChevoletEva HulstaertLiesbeth FerdinandePiet OstKaren GeboesMarc De ManDirk Van de PutteLaurine VersetVibeke Kruse et al.

Peritumoral endothelial indoleamine 2,3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile

Annabel MeiresonInes ChevoletEva HulstaertLiesbeth FerdinandePiet OstKaren GeboesMarc De ManDirk Van de PutteLaurine VersetVibeke Kruse et al.

A2 Journal Article in ONCOTARGET

Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma

Nora SundahlKatrien De WolfVibeke KruseAnnabel MeiresonDries ReyndersEls GoetghebeurMireille Van GeleReinhart SpeeckaertBenjamin HennartLieve Brochez et al.

A1 Journal Article in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor : case report and literature review

Marlies De BockEva HulstaertVibeke KruseLieve Brochez

A2 Journal Article in CASE REPORTS IN DERMATOLOGY

The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University Hospital

Barbara ClausKaat De PourcqNELE CLOTTENSVibeke KrusePaul GemmelJohan Vandenbroucke

A1 Journal Article in EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE

2017

Bijwerkingen van 'immune checkpoint' inhibitoren : waar dient een huisarts alert op te zijn?

S De KeukeleireTessa KerrePiet OstBarbara De MoerlooseKarim VermaelenLieve BrochezVibeke Kruse

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

Cost-effectiveness and budget effect analysis of a population-based skin cancer screening

Lore PilIsabelle HoorensKatrien VossaertVibeke KruseIsabelle TrommeNiko SpeybroeckLieven AnnemansLieve Brochez

A1 Journal Article in JAMA DERMATOLOGY

The ION-Ghent guidelines for the management of immune related adverse events (irAE's)

Vibeke KruseMax SchreuerKarim VermaelenPiet OstTessa KerreBarbara De MoerlooseLieve Brochez

A2 Journal Article in BELGIAN JOURNAL OF MEDICAL ONCOLOGY

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy

Lieve BrochezInes ChevoletVibeke Kruse

A1 Journal Article in EUROPEAN JOURNAL OF CANCER

2016

Successful strategy to treat a solitary cystic melanoma brain metastasis

Vibeke KruseTom BoterbergMarjan AcouDavid CreytensCaroline Van den BroeckeLieve BrochezGiorgio Hallaert

A1 Journal Article in JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Virale oncogenese van het merkelcelcarcinoom

Eva HulstaertInes ChevoletVibeke KruseLieve Brochez

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

2015

Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?

Ines ChevoletMax SchreuerReinhart SpeeckaertBart NeynsIsabelle HoorensNanja van GeelVibeke KruseBenjamin HennartDelphine AllorgeMireille Van Gele et al.

A1 Journal Article in MELANOMA RESEARCH